South San Francisco, CA March 20, 2023 Press Release New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Data…
Tag: risdiplam
Genentech Presents Data from Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting
South San Francisco, CA May 7, 2019 Genentech Press Release Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting In the dose-finding Part 1 of FIREFISH, infants with…